Five major takeaways from Roche's $ 5B purchase of Spark Therapeutics
L a start with the biggest two messages: Roche's (RHHBY) takeover of $ 5 billion acquisition of Spark Therapeutics (ONCE) means that major pharmaceutical companies are at a full-fledged mall and that gene therapy, expected treatment approach of hereditary diseases, has made great time.
The Wall Street Journal reported Saturday that Roche was negotiating to buy Spark at a 150 percent premium to the smaller company's market value on Friday. On Monday morning, the two companies announced that Roche would buy Spark for $ 4.8 billion, or $ 1[ads1]14.50 per share. Here are five things to keep in mind this news for anyone who cares about the biotech industry.
Unlock this article by subscribing to STAT Plus and enjoy the first 30 days for free!
GOT STARTED
What is it?
STAT Plus is a premium subscription that provides daily market-flowing biopharma coverage and thorough science reporting from a team of decades of industry experience.
What's with?
- Authentic biopharma coverage and analysis, interviews with industry pioneers, policy analysis and first look at groundbreaking laboratories and early stage research
- Online events and panel discussions across the country
- ] Monthly subscriber-only live chat with our journalists and experts in the area
- Discounted tickets for industry events and access to early birds for industrial reports
